Trial Outcomes & Findings for Phase I Study of MOv18 IgE (NCT NCT02546921)

Last Updated: 2023-06-05

Results Overview

Reported safety information in the form of AEs, categorised according to Medical Dictionary for Regulatory Activities (MedDRA) version (v) 24.0 and graded for severity according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.02. AEs will be assessed by the reporting study doctors for a causal relationship to MOv18 IgE. Count of AEs by arm.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

26 participants

Primary outcome timeframe

From the date of written informed consent and until the end of safety follow up period for MOv18 IgE, a median of 88.5 days (range: 13 to 181 days).

Results posted on

2023-06-05

Participant Flow

Trial participants were enrolled at four trial sites between 18 November 2015 and 05 August 2021.

Participant milestones

Participant milestones
Measure	MOv18 IgE Cohort 1 MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Overall Study STARTED	2	8	6	3	3	3	1
Overall Study COMPLETED	1	2	4	3	2	2	1
Overall Study NOT COMPLETED	1	6	2	0	1	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	MOv18 IgE Cohort 1 MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Overall Study Adverse Event	0	5	2	0	0
Overall Study Evidence of Disease Progression	1	0	0	1	0
Overall Study Patient Choice	0	1	0	0	1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	Total n=26 Participants Total of all reporting groups
Age, Continuous	61 years n=2 Participants	58.5 years n=8 Participants	59.5 years n=6 Participants	65 years n=3 Participants	54 years n=3 Participants	63 years n=3 Participants	75 years n=1 Participants	60 years n=26 Participants
Sex: Female, Male Female	2 Participants n=2 Participants	8 Participants n=8 Participants	6 Participants n=6 Participants	3 Participants n=3 Participants	3 Participants n=3 Participants	3 Participants n=3 Participants	1 Participants n=1 Participants	26 Participants n=26 Participants
Sex: Female, Male Male	0 Participants n=2 Participants	0 Participants n=8 Participants	0 Participants n=6 Participants	0 Participants n=3 Participants	0 Participants n=3 Participants	0 Participants n=3 Participants	0 Participants n=1 Participants	0 Participants n=26 Participants
Race and Ethnicity Not Collected	—	—	—	—	—	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Region of Enrollment United Kingdom	2 participants n=2 Participants	8 participants n=8 Participants	6 participants n=6 Participants	3 participants n=3 Participants	3 participants n=3 Participants	3 participants n=3 Participants	1 participants n=1 Participants	26 participants n=26 Participants

PRIMARY outcome

Timeframe: From the date of written informed consent and until the end of safety follow up period for MOv18 IgE, a median of 88.5 days (range: 13 to 181 days).

Population: All enrolled participants who received at least one dose of MOv18 IgE by IV infusion, intradermally or as a skin prick test.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) Considered to be at Least Possibly Related to MOv18 IgE No. participants at least one Related SAEs	0 Participants	5 Participants	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants	—
Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) Considered to be at Least Possibly Related to MOv18 IgE No. participants at least one Related NSAEs	0 Participants	5 Participants	5 Participants	3 Participants	3 Participants	3 Participants	1 Participants	—

PRIMARY outcome

Timeframe: From first dose onwards until completion of Cycle 1 (3 weeks).

Population: All enrolled participants who received at least one dose of MOv18 IgE by IV infusion, intradermally or as a skin prick test.

DLTs graded for severity using the NCI CTCAE v4.02, measured by count of participants per arm. Two DLTs were reported; however, following review of the data, it was determined that events of this nature did not constitute DLTs. The trial protocol was updated so that if further similar events occurred then would not be considered as DLTs but the events already reported remain categorised as DLTs.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—

PRIMARY outcome

Timeframe: From the date of written informed consent and until the end of safety follow up period for MOv18 IgE, a median of 88.5 days (range: 13 to 181 days).

Population: All enrolled participants who received at least one dose of MOv18 IgE by IV infusion, intradermally or as a skin prick test.

AEs judged to be due to systemic mast cell degranulation (i.e. anaphylaxis). No dose independent significant toxicities were reported. However, one event of anaphylactic reaction was classified as a DLT at the time of occurrence but, following review of the data, the trial protocol was updated. This meant that any future events of anaphylaxis would have been classified as dose independent toxicities, but the event already reported remained as a DLT.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Number of Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	0 Dose Independent Significant Toxicities	—

PRIMARY outcome

Timeframe: From the date of written informed consent and until the end of safety follow up period for MOv18 IgE, a median of 88.5 days (range: 13 to 181 days).

Reported safety information in the form of haematological or biochemical abnormalities that were reported as AEs and graded for severity according to NCI CTCAE v4.02.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Number of Participants With Grade ≥2 Laboratory Parameter AEs Reported No. participants at least one Haem Grade >=2 AE	0 Participants	4 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—
Number of Participants With Grade ≥2 Laboratory Parameter AEs Reported No. participants at least one Biochem Grade >=2 AE	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Radiological disease response assessment at screening/baseline and every 6 weeks to end of treatment, a median of 56.5 days (range: 38 to 124 days).

Population: Eligible participants who received at least one complete IV dose of MOv18 IgE and had a baseline and at least one post-baseline assessment of disease according to RECIST v1.1. Although 13 participants were initially reported to have a best response of SD, 2 of these participants were not evaluable for SD, as the assessment was performed \<6 weeks after the first IV infusion of MOv18 IgE. Therefore, the total number (%) of participants with SD is reported here as 11 (55.0%).

Best radiological response observed according to RECIST v1.1, presented per arm by count of participants. RECIST responses include complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). For a response to be defined as SD, the criteria must have been met at least once at a minimum interval of 6 weeks after study entry.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=26 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Antitumour Activity (Best Response) of MOv18 IgE Measured According to the Response Evaluation Criteria in Solid Tumours (RECIST) v 1.1 Not evaluable	2 Participants	—	—	—	—	—	—	—
Antitumour Activity (Best Response) of MOv18 IgE Measured According to the Response Evaluation Criteria in Solid Tumours (RECIST) v 1.1 Stable disease	11 Participants	—	—	—	—	—	—	—
Antitumour Activity (Best Response) of MOv18 IgE Measured According to the Response Evaluation Criteria in Solid Tumours (RECIST) v 1.1 Progressive disease	7 Participants	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Disease response assessment at screening/baseline and every six weeks, if clinically appropriate for tumour type, to end of treatment, for a median of 34 days (range: 5 to 91 days).

Population: All eligible participants who received at least one complete IV dose of MOv18 IgE and who had elevated CA125 at baseline (\>35 kU/L).

The percentage change in CA125 levels from baseline to the last measurement taken on-treatment, presented as a median (minimum, maximum) for each arm.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=1 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=3 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=4 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Antitumour Activity Measured by the Percentage Change in Cancer Antigen 125 (CA125) Tumour Marker Levels During the Trial, in Participants With Elevated CA125 at Baseline	41.38 % change from baseline CA125 level Interval 41.38 to 41.38	59.04 % change from baseline CA125 level Interval -14.13 to 227.52	52.79 % change from baseline CA125 level Interval 15.12 to 80.36	118.13 % change from baseline CA125 level Interval -32.31 to 264.9	45.41 % change from baseline CA125 level Interval 14.75 to 100.41	15.93 % change from baseline CA125 level Interval 13.82 to 31.86	144.14 % change from baseline CA125 level Interval 144.14 to 144.14	—

SECONDARY outcome

Timeframe: Cohorts 1-7: Cycle 1 Day 1 within 24 hours (h) predose, then 30 mins postdose and 2, 4, 6 and 24 h postdose. Cohort 7 only (intrapatient dose escalation): Cycle 2 Day 1 predose, then 30 mins postdose and 2, 4, 6 and 24 h postdose. Each cycle = 21 days.

Population: All participants who received a complete IV infusion of MOv18 IgE on Cycle 1, Day 1 and, for Cohort 7 only, Cycle 2 Day 1. For this outcome measure, data for Cohort 7 are reportedly separately by dose level.

Area under the serum concentration-time curve from time 0 to 24 hours after IV MOv18 IgE administration, evaluated using an enzyme linked immunosorbent assay (ELISA) method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of Pharmacokinetic (PK) Parameter Area Under the Concentration-Time Curve From Time 0 to 24 Hours of MOv18 IgE	NA ng/mL.h Standard Deviation NA In one participant, MOv18 IgE could not be quantified in samples at any time point. In the other participant, MOv18 IgE could only be detected up to 7 hours postdose	130 ng/mL.h Standard Deviation 76	303 ng/mL.h Standard Deviation 159	222 ng/mL.h Standard Deviation 42	726 ng/mL.h Standard Deviation 113	761 ng/mL.h Standard Deviation NA Only one patient had evaluable data at this timepoint	2134 ng/mL.h Standard Deviation NA Only one patient had evaluable data at this timepoint	5573 ng/mL.h Standard Deviation NA Only one patient had evaluable data at this timepoint

SECONDARY outcome

Timeframe: Cohorts 1-7: Cycle 1 Day 1 <24 h predose, then 30 mins postdose and 2, 4, 6, 24 and 48 h postdose; Cycle 1 Day 8 predose. Cohort 7 only (intrapatient escalation): Cycle 2 Day 1 predose, then 30 mins and 2, 4, 6 and 24 h postdose. Each cycle = 21 days.

Cmax in serum following IV MOv18 IgE administration was analysed using an ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) of MOv18 IgE	2.3 ng/mL Standard Deviation NA Only one patient had evaluable data at this timepoint	9.4 ng/mL Standard Deviation 6.8	31.8 ng/mL Standard Deviation 11.4	29.7 ng/mL Standard Deviation 4.6	86.8 ng/mL Standard Deviation 18.3	75.7 ng/mL Standard Deviation NA Only one patient had evaluable data at this timepoint	196.7 ng/mL Standard Deviation NA Only one patient had evaluable data at this timepoint	368.2 ng/mL Standard Deviation NA Only one patient had evaluable data at this timepoint

SECONDARY outcome

Serum samples were analysed to determine the Tmax of MOv18 IgE following IV administration using an ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of PK Parameter Time to Reach Maximum Observed Serum Concentration (Tmax) of MOv18 IgE	3.5 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	2.2 Hour Standard Deviation 0.6	2.2 Hour Standard Deviation 0.5	2.2 Hour Standard Deviation 0.1	2.0 Hour Standard Deviation 0.3	2.1 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	1.0 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	0.9 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint

SECONDARY outcome

Serum samples were analysed to determine the concentrations of MOv18 IgE using a previously developed ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of PK Parameter Terminal Half Life for MOv18 IgE	NA Hour Standard Deviation NA In one participant, MOv18 IgE could not be quantified in samples at any time point. In the other participant, MOv18 IgE could only be detected up to 7 hours postdose	10.5 Hour Standard Deviation 0.6	9.9 Hour Standard Deviation 2.4	7.4 Hour Standard Deviation 0.3	9.2 Hour Standard Deviation 0.2	15.0 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	10.0 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	NA Hour Standard Deviation NA Half-life was not calculated for the 12 mg dose level due to a skewed value observed at the 6 h time point

SECONDARY outcome

Serum samples were analysed to determine the MRT of MOv18 IgE following IV administration, using an ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of the PK Parameter Mean Residence Time (MRT) of MOv18 IgE	NA Hour Standard Deviation NA In one participant, MOv18 IgE could not be quantified in samples at any time point. In the other participant, MOv18 IgE could only be detected up to 7 hours postdose	13.2 Hour Standard Deviation 1.1	12.5 Hour Standard Deviation 3.4	8.9 Hour Standard Deviation 0.3	11.4 Hour Standard Deviation 1.0	19.9 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	11.8 Hour Standard Deviation NA Only one patient had evaluable data at this timepoint	NA Hour Standard Deviation NA MRT was not calculated for the 12 mg dose level due to a skewed value observed at the 6 h time point

SECONDARY outcome

Serum samples were analysed to determine the CLT of MOv18 IgE following IV administration, using an ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of the PK Parameter Total Body Clearance (CLT) of MOv18 IgE	NA L/h Standard Deviation NA In one participant, MOv18 IgE could not be quantified in samples at any time point. In the other participant, MOv18 IgE could only be detected up to 7 h postdose	1.9 L/h Standard Deviation 0.8	1.6 L/h Standard Deviation 0.6	2.8 L/h Standard Deviation 0.5	1.7 L/h Standard Deviation 0.2	2.7 L/h Standard Deviation NA Only one patient had evaluable data at this timepoint	2.3 L/h Standard Deviation NA Only one patient had evaluable data at this timepoint	0.8 L/h Standard Deviation NA Only one patient had evaluable data at this timepoint

SECONDARY outcome

Serum samples were analysed to determine the Vss of MOv18 IgE following IV administration, using an ELISA method. Not all participants were analysed at all time points.

Outcome measures

Outcome measures
Measure	MOv18 IgE Cohort 1 n=2 Participants MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=5 Participants MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=5 Participants MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=2 Participants MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=2 Participants MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=1 Participants MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 Participants MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 After Intra-patient Dose Escalation n=1 Participants MOv18 IgE: after receiving three IV infusions of 6 mg MOv18 IgE in Cycle 1, the dose will be escalated. The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with with 2 μg/mL MOv18 IgE solution, for safety assessment.
Measurement of the PK Parameter Volume of Distribution (Vss) of MOv18 IgE	NA L Standard Deviation NA In one participant, MOv18 IgE could not be quantified in samples at any time point. In the other participant, MOv18 IgE could only be detected up to 7 h postdose	24.4 L Standard Deviation 10.2	18.7 L Standard Deviation 6.2	25.9 L Standard Deviation 5.4	20.1 L Standard Deviation 4.6	53.2 L Standard Deviation NA Only one patient had evaluable data at this timepoint	27.3 L Standard Deviation NA Only one patient had evaluable data at this timepoint	38.3 L Standard Deviation NA Only one patient had evaluable data at this timepoint

Adverse Events

MOv18 IgE Cohort 1

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

MOv18 IgE Cohort 2

Serious events: 6 serious events

Other events: 7 other events

Deaths: 0 deaths

MOv18 IgE Cohort 3

Serious events: 5 serious events

Other events: 6 other events

Deaths: 0 deaths

MOv18 IgE Cohort 4

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

MOv18 IgE Cohort 5

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

MOv18 IgE Cohort 6

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

MOv18 IgE Cohort 7

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	MOv18 IgE Cohort 1 n=2 participants at risk MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 participants at risk MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 participants at risk MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 participants at risk MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 participants at risk MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 participants at risk MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 participants at risk MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Ascites	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Intestinal obstruction	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Intra-abdominal fluid collection	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Nausea	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Vomiting	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Oedema peripheral	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Pyrexia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Immune system disorders Anaphylactic reaction	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Kidney infection	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Skin test positive	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	62.5% 5/8 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Nervous system disorders Seizure	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Hypotension	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).

Other adverse events

Other adverse events
Measure	MOv18 IgE Cohort 1 n=2 participants at risk MOv18 IgE: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.	MOv18 IgE Cohort 2 n=8 participants at risk MOv18 IgE: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 3 n=6 participants at risk MOv18 IgE: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 4 n=3 participants at risk MOv18 IgE: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 5 n=3 participants at risk MOv18 IgE: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 6 n=3 participants at risk MOv18 IgE: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.	MOv18 IgE Cohort 7 n=1 participants at risk MOv18 IgE: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks. Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Psychiatric disorders Insomnia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Joint range of motion decreased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Eye disorders Lacrimation increased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Lymphocyte count decreased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Muscle spasms	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Muscle twitching	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Abdominal distension	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Abdominal pain lower	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Abdominal pain upper	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Blood and lymphatic system disorders Anaemia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	62.5% 5/8 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Ascites	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Blood albumin decreased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Blood alkaline phosphatase increased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Blood creatinine increased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Blood uric acid increased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Candida infection	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Chest discomfort	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Chills	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Nervous system disorders Cognitive disorder	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Psychiatric disorders Confusional state	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Constipation	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Diarrhea	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	37.5% 3/8 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Nervous system disorders Dizziness	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Nervous system disorders Dizziness postural	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Eczema	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Electrocardiogram QT prolonged	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Fatigue	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	37.5% 3/8 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Flatulence	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Flushing	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Gastroesophageal reflux disease	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Groin infection	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Nervous system disorders Headache	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	25.0% 2/8 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Hordeolum	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Hot flush	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Renal and urinary disorders Hydronephrosis	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Hypertension	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Hypotension	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Nausea	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	25.0% 2/8 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	50.0% 3/6 • Number of events 4 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Investigations Neutrophil count decreased	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Non-cardiac chest pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Oedema peripheral	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Eye disorders Orbital oedema	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Reproductive system and breast disorders Pelvic pain	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Eye disorders Periorbital oedema	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Peripheral swelling	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Renal and urinary disorders Pollakiuria	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Injury, poisoning and procedural complications Postoperative wound complication	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	37.5% 3/8 • Number of events 7 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 9 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 3/3 • Number of events 11 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 4 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Rash	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	66.7% 2/3 • Number of events 10 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Rhinitis	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 2/6 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Immune system disorders Seasonal allergy	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
General disorders Secretion discharge	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Stomatitis	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Infections and infestations Urinary tract infection	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	12.5% 1/8 • Number of events 2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	50.0% 3/6 • Number of events 8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 3/3 • Number of events 12 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 3/3 • Number of events 12 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 3/3 • Number of events 10 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Vascular disorders Vena cava thrombosis	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	16.7% 1/6 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Gastrointestinal disorders Vomiting	50.0% 1/2 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	50.0% 3/6 • Number of events 5 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	100.0% 1/1 • Number of events 3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).
Skin and subcutaneous tissue disorders Xeroderma	0.00% 0/2 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/8 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/6 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	33.3% 1/3 • Number of events 1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/3 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).	0.00% 0/1 • Safety data were collected from the date of written informed consent and continued until 70 days after the last dose of MOv18 IgE, an average (median) of 88.5 days (range: 13-181).

Additional Information

Regulatory Affairs Manager

Cancer Research UK Centre for Drug Development

Phone: +44 203 4696878

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place